Reduction of muscarinic cholinergic receptors in mouse striatum by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its recovery by levodopa treatment.
The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration on muscarinic chelinergic receptors (mACh-R) in the mouse striatum and their modulation with levopoda treatment were studied. Striatal mACh-R binding decreased significantly 6 weeks after MPTP treatment, but recovered to control levels 2 weeks after treatment with levodopa. The changes in the mACh-R were caused by changes in receptor binding capacity but not associated with receptor binding affinity. These results suggests that striatal mACh-R is dependent on dopaminergic activity in the striatum.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011725:Pyridines / Q000633:toxicity*; D011813:Quinuclidinyl Benzilate; D011976:Receptors, Muscarinic / Q000187:drug effects*
D011725:Pyridines; D011976:Receptors, Muscarinic; D007980:Levodopa; D011813:Quinuclidinyl Benzilate; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine